Pulmonary arterial hypertension (PAH) remains a highly fatal syndrome despite recent advancements in its treatment. PAH is an occlusive disease of the pulmonary arteries, leading to serious hemodynamic abnormality, right heart failure, and premature death, and has an estimated 5-year survival of 50%. New candidate drugs have shown promise in potentially providing improved treatment for PAH. However, the clinical application of these agents has generally been hampered by their systemic toxicity/adverse side effects, and currently available therapies provide only a limited positive effect on PAH patients. PAH is progressive and there is no cure. Treatment focuses on decreasing symptoms and improving quality of life for patients.
Our CAR peptide addresses an unmet need in PAH patient care by providing a targeting technology to make existing PAH therapies more effective and pulmonary-specific, reducing unwanted side effects of systemic therapies. Simple co-administration of CAR selectively enhances the pulmonary vascular effects of systemically administered vasodilators, by reducing right ventricular systolic pressure without also reducing systemic arterial pressure. CAR fills an important niche in PAH care by enabling pulmonary arterial selective drug delivery, an important advance in PAH targeted therapy.
- Learn more about the CAR peptide works
- Applications for the CAR peptide
- CAR Peptide Scientific Articles
- For inquiries about CAR peptide and other VBS pharmaceutical products,
please contact us at email@example.com
DISCLAIMER: The material provided on this site is strictly for informational purposes. Do not use this site as a substitute for medical care or medical advice. Please consult with your physician or other medical care provider regarding any medical questions you may have.